Altered Immune Profiles of Natural Killer Cells in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Aug 12

PMID 27513564

Citations 8

Authors

Qiong-Fang Zhang

Jian-Ying Shao

Wen-Wei Yin

Yang Xia

Ling Chen

Xing Wang

Huai-Dong Hu

Peng Hu

Hong Ren

Da-Zhi Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Natural killer (NK) cells are the main effective component of the innate immune system that responds to chronic hepatitis B (CHB) infection. Although numerous studies have reported the immune profiles of NK cells in CHB patients, they are limited by inconsistent results. Thus, we performed a meta-analysis to characterize reliably the immune profiles of NK cells after CHB infection, specifically frequency, phenotype, and function.

Methods: A literature search of the computer databases MEDLINE, PUBMED, EMBASE, and Cochrane Center Register of Controlled Trails was performed and 19 studies were selected. The standard mean difference (SMD) and 95% confidence interval (CI) of each continuous variable was estimated with a fixed effects model when I2 < 50% for the test for heterogeneity, or the random effects model otherwise. Publication bias was evaluated using Begg's and Egger's tests.

Results: The meta-analysis of publications that reported frequency of peripheral NK cells showed that NK cell levels in CHB patients were significantly lower compared with that of healthy controls. A higher frequency of CD56bright NK subsets was found in CHB patients, but the CD56dim NK subsets of CHB patients and healthy controls were similar. CHB patients before and after antiviral therapy with nucleotide analogues (NUCs) showed no statistical difference in NK frequency. The activating receptors were upregulated, whereas inhibitory receptors were comparable in the peripheral NK cells of CHB individuals and healthy controls. NK cells of CHB patients displayed higher cytotoxic potency as evidenced by CD107a protein levels and conserved potency to produce interferon-gamma (IFNγ), compared with their healthy counterparts.

Conclusion: Our results revealed that CHB patients had a lower frequency of NK cells compared with healthy individuals not treatable with antiviral NUC therapy. With an activating phenotype, NK cells in CHB patients showed better cytotoxic potency and conserved IFNγ production.

Citing Articles

NK cell phenotypic profile during active TB in people living with HIV-evolution during TB treatment and implications for bacterial clearance and disease severity.

Maseko T, Rambaran S, Ngubane S, Lewis L, Ngcapu S, Hassan-Moosa R Sci Rep. 2023; 13(1):11726.

PMID: 37474556 PMC: 10359304. DOI: 10.1038/s41598-023-38766-7.

Hepatitis B functional cure and immune response.

Zheng J, Wang Z, Feng B Front Immunol. 2022; 13:1075916.

PMID: 36466821 PMC: 9714500. DOI: 10.3389/fimmu.2022.1075916.

Peripheral Immune Cells Exhaustion and Functional Impairment in Patients With Chronic Hepatitis B.

Jin X, Yan Z, Lu L, Lu S, Zhang G, Lin W Front Med (Lausanne). 2021; 8:759292.

PMID: 34782855 PMC: 8589627. DOI: 10.3389/fmed.2021.759292.

Serum HBV pregenomic RNA exhibited opposite associations with NKdim and NKbright cell immunity in treatment-naïve chronic hepatitis B patients.

Gu Y, Huang Z, Li X, Chen Y, Liao C, Bi Y Biosci Rep. 2021; 41(7).

PMID: 34151357 PMC: 8255538. DOI: 10.1042/BSR20210600.

NKG2C+ natural killer cell function improves the control of HBV replication in individuals with acute HIV infection coinfected with HBV.

Song T, Li L, Su B, Liu L, Liu Y, Yang X Medicine (Baltimore). 2020; 99(18):e20073.

PMID: 32358389 PMC: 7440068. DOI: 10.1097/MD.0000000000020073.

References

Mondelli M, Varchetta S, Oliviero B . Natural killer cells in viral hepatitis: facts and controversies. Eur J Clin Invest. 2010; 40(9):851-63. DOI: 10.1111/j.1365-2362.2010.02332.x. View

Tjwa E, van Oord G, Hegmans J, Janssen H, Woltman A . Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol. 2010; 54(2):209-18. DOI: 10.1016/j.jhep.2010.07.009. View

Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z . Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol. 2006; 177(1):739-47. DOI: 10.4049/jimmunol.177.1.739. View

Zhao J, Li Y, Jin L, Zhang S, Fan R, Sun Y . Natural killer cells are characterized by the concomitantly increased interferon-γ and cytotoxicity in acute resolved hepatitis B patients. PLoS One. 2012; 7(11):e49135. PMC: 3486810. DOI: 10.1371/journal.pone.0049135. View

Zhang Z, Chen D, Yao J, Zhang H, Jin L, Shi M . Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B. Clin Immunol. 2006; 122(2):173-80. DOI: 10.1016/j.clim.2006.09.006. View

Matthews G, Nelson M . The management of chronic hepatitis B infection. Int J STD AIDS. 2001; 12(6):353-7. DOI: 10.1258/0956462011923273. View

Rehermann B, Bertoletti A . Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology. 2014; 61(2):712-21. PMC: 4575407. DOI: 10.1002/hep.27323. View

Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A . Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut. 2009; 58(7):974-82. DOI: 10.1136/gut.2008.163600. View

Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E . The trafficking of natural killer cells. Immunol Rev. 2007; 220:169-82. PMC: 7165697. DOI: 10.1111/j.1600-065X.2007.00563.x. View

10.

Yan M, Mao H, Liu Q, Wang W, Li Y . Elevated levels of serum soluble E-selectin in patients with chronic hepatitis B: Correlation with T lymphocyte subsets, NK cells and liver inflammation. Hepatol Res. 2006; 35(2):111-7. DOI: 10.1016/j.hepres.2006.03.006. View

11.

Zhao P, Jia F, Shan Y, Ji H, Feng J, Niu J . Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir. Clin Exp Pharmacol Physiol. 2013; 40(3):190-6. DOI: 10.1111/1440-1681.12048. View

12.

Zhang J, Zhang Z, Lin F, Zou Z, Xu R, Jin L . Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology. 2009; 51(1):81-91. DOI: 10.1002/hep.23273. View

13.

Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z . TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog. 2012; 8(3):e1002594. PMC: 3305436. DOI: 10.1371/journal.ppat.1002594. View

14.

Crotta S, Stilla A, Wack A, DAndrea A, Nuti S, DOro U . Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med. 2002; 195(1):35-41. PMC: 2196014. DOI: 10.1084/jem.20011124. View

15.

Petitti D . Approaches to heterogeneity in meta-analysis. Stat Med. 2001; 20(23):3625-33. DOI: 10.1002/sim.1091. View

16.

Webster G, Reignat S, Maini M, Whalley S, Ogg G, King A . Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology. 2000; 32(5):1117-24. DOI: 10.1053/jhep.2000.19324. View

17.

Peppa D, Micco L, Javaid A, Kennedy P, Schurich A, Dunn C . Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog. 2010; 6(12):e1001227. PMC: 3003000. DOI: 10.1371/journal.ppat.1001227. View

18.

Kim N, Saudemont A, Webb L, Camps M, Ruckle T, Hirsch E . The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood. 2007; 110(9):3202-8. DOI: 10.1182/blood-2007-02-075366. View

19.

Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D . Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology. 2009; 137(3):1151-60, 1160.e1-7. DOI: 10.1053/j.gastro.2009.05.047. View

20.

Rehermann B, Naoumov N . Immunological techniques in viral hepatitis. J Hepatol. 2007; 46(3):508-20. DOI: 10.1016/j.jhep.2007.01.002. View